Loading patent…
AssigneeThe Johns Hopkins University
InventorsGregory Riggins, Renyuan Bai, Verena Staedtke, Avadhut D. Joshi, Tara Williamson
Estimating the term…
Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.
A pharmaceutical formulation of mebendazole wherein at least 90% of the mebendazole in the formulation is polymorph C, and wherein the formulation is granulated.
A pharmaceutical formulation of mebendazole comprising polymorph C and an inhibitor of P-glycoprotein.
A pharmaceutical formulation of mebendazole and an NSAID.
A method to monitor anti-cancer potency of a pharmaceutical formulation of mebendazole, comprising:
A kit for treating or reducing risk of tumors, comprising:
A method of treating or reducing risk of a tumor in a human comprising:
A method of reducing risk of a tumor in a human comprising:
Dependencies are inferred from the claim text.